Impact of Vitamin D on Hormones, Metabolism, & Brain Health: A Comprehensive Systems Biology Approach in the Context of a Global Deficiency Epidemic

#vitamind #neuroscience #neuropsychiatry #neuroendocrine #neuroinflammation #systemsbiology #mentalhealth #wellness #nutrition #publichealth #gutbrainaxis #gutmicrobiome #diet #vitamins

Explore the vital role of vitamin D in neuropsychiatric health, its impact on depression and anxiety disorders, and the potential benefits of supplementation.

"Vitamin D is not only a vitamin, but also an important hormone with many essential functions in the body, including brain health." - Dr. Michael F. Holick, Ph.D., M.D., renowned vitamin D expert and author of "The Vitamin D Solution."

Vitamin D is a fat-soluble nutrient that plays a vital role in numerous physiological processes, from bone health and calcium homeostasis to immune function and cellular growth regulation (Holick, 2007). Emerging research highlights the significance of vitamin D in neuropsychiatric health, revealing its involvement in cognitive function, mood regulation, and the pathophysiology of various mental disorders (Eyles, Burne, & McGrath, 2013). Alarmingly, vitamin D deficiency is now recognized as a global epidemic, with approximately 35-55% of the world's population affected (Rihal et al., 2022). We will briefly discuss the importance of vitamin D in metabolism and neuropsychiatric health, including its role in mental disorders and the implications of the deficiency epidemic on global mental health.

Vitamin D deficiency is now recognized as a global epidemic, with approximately 35-55% of the world's population affected --Rihal et al., 2022.

Vitamin D: From Synthesis to Neuropsychiatric Functions

The primary source of vitamin D is sunlight-induced synthesis in the skin, with a small portion obtained through dietary intake (Holick, 2007). Once synthesized or consumed, vitamin D undergoes a two-step hydroxylation process in the liver and kidneys, converting it to its active form, calcitriol (1,25-dihydroxyvitamin D) (Holick, 2007). Calcitriol acts as a hormone, binding to the vitamin D receptor (VDR) in various tissues, including the brain (Eyles et al., 2013).

Vitamin D affects neurogenesis, synaptic plasticity, and neuroprotection through its antioxidant, anti-inflammatory, and immunomodulatory properties --Mayne & Burne, 2019.

Research has demonstrated the presence of VDRs and enzymes required for vitamin D metabolism in brain regions crucial for cognition, memory, and emotional regulation (Eyles et al., 2013). Vitamin D has been found to modulate neurotransmitter synthesis, including serotonin, which plays a central role in mood regulation and the etiology of mental disorders such as depression, bipolar disorder, and schizophrenia (Patrick & Ames, 2015). Furthermore, vitamin D affects neurogenesis, synaptic plasticity, and neuroprotection through its antioxidant, anti-inflammatory, and immunomodulatory properties (Mayne & Burne, 2019).

Vitamin D Deficiency and Mental Health

A growing body of evidence links vitamin D deficiency to various neuropsychiatric disorders, including depression, bipolar disorder, schizophrenia, and attention deficit hyperactivity disorder (ADHD) (Anglin et al., 2013; Gracious et al., 2012; Rihal et al., 2022). A meta-analysis by Anglin et al. (2013) found a significant association between low vitamin D levels and depression in adults. In another study, low vitamin D levels were associated with an increased risk of schizophrenia, with deficient individuals 2.16 times more likely to have the disorder than those with sufficient levels (McGrath et al., 2010).

Similarly, vitamin D deficiency has been implicated in ADHD, with Bener et al. (2014) reporting a higher deficiency prevalence in children with ADHD compared to healthy controls. Researchers have suggested that inadequate vitamin D levels may contribute to the development of mental disorders by disrupting serotonin synthesis, impairing neuroplasticity, and increasing inflammation (Patrick & Ames, 2015; Mayne & Burne, 2019).

Inflammation has been increasingly recognized as a critical mediator in the pathophysiology of mood disorders, with studies consistently reporting elevated levels of pro-inflammatory cytokines in individuals with major depressive disorder (MDD) and bipolar disorder (BD) (Rosenblat et al., 2014). A study by Marques-Deak et al. (2007) found that women with MDD exhibited significantly higher levels of pro-inflammatory cytokines compared to healthy controls. Inflammation may contribute to the development and progression of mood disorders by directly affecting neurotransmitter levels, dysregulating the hypothalamic-pituitary-adrenal (HPA) axis, and impairing neuroplasticity (Rosenblat et al., 2014).

The Epidemic of Vitamin D Deficiency: Implications for Global Mental Health

The widespread prevalence of vitamin D deficiency is a significant public health concern, as inadequate levels of this essential nutrient may exacerbate the burden of mental disorders worldwide (Rihal et al., 2022). The deficiency epidemic is attributed to various factors, including reduced sun exposure due to urbanization, indoor lifestyles, increased use of sunscreens, dietary inadequacies, and genetic factors (Holick, 2007; Pludowski et al., 2014).

Addressing the global vitamin D deficiency epidemic requires a multifaceted approach, including public health initiatives to increase awareness, promote safe sun exposure, and encourage dietary supplementation (Pludowski et al., 2014). Moreover, healthcare professionals should be mindful of the potential neuropsychiatric consequences of vitamin D deficiency and consider screening and supplementation in at-risk populations.

The Role of Vitamin D in Major Depressive Disorder

Major depressive disorder (MDD) is a common and debilitating psychiatric illness affecting millions worldwide. It is characterized by persistent low mood, loss of interest in activities, and cognitive impairments, among other symptoms (American Psychiatric Association, 2013). In recent years, research has increasingly focused on the potential role of vitamin D in the development and treatment of MDD. Vitamin D, a fat-soluble vitamin, is primarily known for its role in calcium homeostasis and bone health. Still, it also has a wide range of immune, cardiovascular, and brain functions (Holick, 2007).

Several epidemiological studies have demonstrated an association between low serum levels of 25-hydroxyvitamin D [25(OH)D], the primary circulating form of vitamin D, and an increased risk of MDD (Anglin et al., 2013; Ju et al., 2013). A meta-analysis of cross-sectional and prospective studies found a significant inverse relationship between 25(OH)D levels and the risk of depression, suggesting that individuals with lower vitamin D levels were more likely to develop MDD (Anglin et al., 2013).

the role of vitamin D in modulating the production and function of neurotransmitters, such as serotonin, dopamine, and norepinephrine, which are known to be involved in the pathophysiology of MDD (Patrick & Ames, 2014).

The biological mechanisms underlying the association between vitamin D and MDD are not fully understood, but several hypotheses have been proposed. One possible explanation is the role of vitamin D in modulating the production and function of neurotransmitters, such as serotonin, dopamine, and norepinephrine, which are known to be involved in the pathophysiology of MDD (Patrick & Ames, 2014). Vitamin D receptors are widely expressed in the brain, particularly in areas involved in mood regulation, such as the prefrontal cortex, hippocampus, and hypothalamus (Eyles et al., 2005). Animal studies have shown that vitamin D deficiency leads to altered serotonin levels and reduced expression of serotonin receptors in the brain (Patrick & Ames, 2014).

Another potential mechanism linking vitamin D to MDD is its role in neuroinflammation. Emerging evidence suggests that inflammation plays a critical role in the pathogenesis of MDD, as pro-inflammatory cytokines are elevated in the blood and cerebrospinal fluid of individuals with depression (Dantzer et al., 2008). Vitamin D has been shown to have anti-inflammatory properties by suppressing the production of pro-inflammatory cytokines and promoting the production of anti-inflammatory cytokines (Hewison, 2010). Consequently, vitamin D deficiency may contribute to a heightened inflammatory state, which in turn may increase the risk of developing MDD.

Given the potential role of vitamin D in the pathophysiology of MDD, researchers have investigated the therapeutic effects of vitamin D supplementation on depressive symptoms. A systematic review and meta-analysis of randomized controlled trials found that vitamin D supplementation had a small but significant antidepressant effect, particularly in individuals with clinically significant depressive symptoms or vitamin D deficiency (Spedding, 2014). Another meta-analysis also supported the use of vitamin D supplementation as an adjunct to standard antidepressant medications for improving depressive symptoms (Shaffer et al., 2014).

In conclusion, there is growing evidence supporting the role of vitamin D in the development and treatment of MDD. Vitamin D deficiency has been linked to an increased risk of depression, and supplementation may offer a potential therapeutic approach for individuals with MDD. Further research is needed to elucidate the underlying biological mechanisms and establish optimal dosing and treatment regimens for vitamin D supplementation in MDD.

The role of vitamin D in major depressive disorder (MDD) has garnered significant interest in recent years, as the prevalence of vitamin D deficiency has become a global health concern (Holick, 2007). Moreover, several studies have shown that individuals with depression exhibit lower vitamin D levels than the general population (Anglin et al., 2013; Ju et al., 2013).

Vitamin D receptors (VDRs) are found throughout the human brain, including areas implicated in mood regulation, such as the prefrontal cortex, hippocampus, and hypothalamus (Eyles et al., 2005). The presence of VDRs in these regions suggests a potential influence of vitamin D on neurotransmission and neural processes related to mood (Patrick & Ames, 2014).

One mechanism by which vitamin D may affect mood is through its impact on inflammation.

See several of my other articles where I discuss the inter-relationships between neuropsychiatric disorders and the neuroimmune and neuro-inflammatory links, HERE and HERE and HERE and HERE. Among others, ;)

Inflammation has been identified as a critical factor in the development of depression, with increased levels of pro-inflammatory cytokines observed in individuals with MDD (Dantzer et al., 2008).

Vitamin D has been shown to have immunomodulatory properties, reducing the production of pro-inflammatory cytokines while enhancing the production of anti-inflammatory cytokines (Hewison, 2010).

Thus, vitamin D deficiency could contribute to developing or exacerbating depressive symptoms by promoting a pro-inflammatory state.

Reminder: vitamin D has been implicated in the regulation of serotonin, a neurotransmitter strongly associated with mood and depression.

Vitamin D has been shown to enhance the expression of the enzyme tryptophan hydroxylase 2, which converts tryptophan to serotonin (Patrick & Ames, 2014). As a result, vitamin D deficiency could lead to reduced serotonin production, contributing to depressive symptoms.

Given the mounting evidence linking vitamin D deficiency to depression, several studies have explored the efficacy of vitamin D supplementation in treating MDD. A meta-analysis by Shaffer et al. (2014) found that vitamin D supplementation significantly reduced depressive symptoms, particularly in individuals with clinically significant depression. Another meta-analysis by Spedding (2014) revealed that vitamin D supplementation effectively reduced depressive symptoms when accounting for study quality and biological flaws.

The role of vitamin D in major depressive disorder is supported by a growing body of evidence that suggests a connection between vitamin D deficiency, inflammation, and serotonin regulation. Vitamin D supplementation has been shown to alleviate depressive symptoms in some individuals, highlighting the potential therapeutic benefits of addressing vitamin D deficiency in the context of depression. Further research is needed to better understand the mechanisms underlying the relationship between vitamin D and depression and determine optimal dosages and treatment strategies for individuals with MDD and vitamin D deficiency.

Vitamin D in Anxiety: OCD, PTSD, and GAD

The role of vitamin D in anxiety disorders, including obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and generalized anxiety disorder (GAD), has also become an area of increasing interest as the prevalence of vitamin D deficiency continues to rise globally (Holick, 2007). While the relationship between vitamin D and anxiety disorders is less established than depression, emerging evidence suggests a potential connection between vitamin D deficiency and the development or exacerbation of anxiety symptoms.

As mentioned, vitamin D receptors (VDRs) are present throughout the brain, including regions associated with anxiety regulation, such as the amygdala, hippocampus, and prefrontal cortex (Eyles et al., 2005). These regions are involved in processing fear and anxiety, suggesting that vitamin D may have a role in modulating anxiety-related neural processes (Patrick & Ames, 2014).

Research has indicated that individuals with anxiety disorders may have lower vitamin D levels than healthy controls. For example, a study by Kheirouri et al. (2018) found that individuals with GAD had significantly lower serum vitamin D levels than the control group. Similarly, a study by Wang et al. (2019) found an association between lower serum vitamin D levels and an increased risk of developing PTSD in a Chinese population.

The relationship between vitamin D deficiency and anxiety disorders may be partly explained by the influence of vitamin D on neurotransmitters, such as serotonin and dopamine, which regulate anxiety (Patrick & Ames, 2014). As mentioned already above, vitamin D has been shown to enhance the expression of tryptophan hydroxylase 2, the enzyme responsible for converting tryptophan to serotonin (Patrick & Ames, 2014). Additionally, vitamin D has been found to modulate the production of tyrosine hydroxylase, a rate-limiting enzyme in the synthesis of dopamine (Garcion et al., 2002). Consequently, vitamin D deficiency could lead to imbalances in these neurotransmitters, potentially contributing to anxiety symptoms.

Furthermore, vitamin D has been implicated in regulating inflammation (as detailed above with multiple ancillary articles linked), which has been associated with developing anxiety disorders (Hoge et al., 2009). Vitamin D has immunomodulatory properties that reduce the production of pro-inflammatory cytokines while enhancing anti-inflammatory cytokine production (Hewison, 2010). As a result, vitamin D deficiency may promote a pro-inflammatory state, potentially contributing to the development or exacerbation of anxiety symptoms.

Despite the emerging evidence, vitamin D supplementation's efficacy in treating anxiety disorders remains inconclusive. A systematic review and meta-analysis by Vellekkatt and Menon (2018) found no significant effect of vitamin D supplementation on anxiety symptoms in randomized controlled trials. However, the authors noted that the included studies were heterogeneous and had small sample sizes, which may have limited the ability to detect a significant effect.

So, the role of vitamin D in anxiety disorders, including OCD, PTSD, and GAD, is an area of growing interest for sure, with evidence suggesting a potential connection between vitamin D deficiency and anxiety symptoms --collateral to the study in neuropsychiatric disorders in general and wellness and general health in the context of a global pandemic of vitamin d deficiency. The mechanisms underlying this relationship may involve the modulation of neurotransmitters and inflammation. Further research is needed better to understand the relationship between vitamin D and anxiety disorders and determine the potential therapeutic benefits of addressing vitamin D deficiency in individuals with anxiety disorders.

Vitamin D, the Gut-Brain Axis, and the Microbiome

The gut-brain axis, a bidirectional communication system between the central nervous and gastrointestinal tract, plays a critical role in neuropsychiatric health. Recent research has highlighted the potential influence of vitamin D on the gut microbiome, which in turn may impact the gut-brain axis and neuropsychiatric diseases (Dinan & Cryan, 2017).

Vitamin D receptors (VDRs) are expressed in various tissues throughout the body, including the gastrointestinal tract, where they regulate the balance of the gut microbiome (Cantorna et al., 2014). The active form of vitamin D, calcitriol, has been found to modulate the immune system and support the growth of beneficial bacteria while inhibiting the growth of harmful bacteria (Sun, 2016). This regulatory effect on the gut microbiome may have implications for the gut-brain axis, as the composition of gut microbiota can influence neurotransmitter production, immune function, and inflammatory processes, all of which have been implicated in neuropsychiatric disorders (Sharon et al., 2016).

Deficiency in vitamin D has been linked to alterations in the gut microbiome and increased susceptibility to neuropsychiatric disorders (Jiang et al., 2020). In a study by Jiang et al. (2020), vitamin D-deficient mice displayed altered gut microbiota composition and increased anxiety-like behaviors. Supplementation with vitamin D3 helped restore gut microbiota balance and reduce anxiety-like behaviors in these mice, suggesting a potential therapeutic role for vitamin D in neuropsychiatric conditions.

Moreover, vitamin D deficiency has been associated with increased intestinal permeability, resulting in "leaky gut" syndrome, allowing harmful substances to enter the bloodstream and potentially exacerbating inflammation and neuropsychiatric symptoms (G??bska et al., 2020). The anti-inflammatory properties of vitamin D may further contribute to its beneficial effects on the gut-brain axis, as inflammation has been implicated in the pathophysiology of various neuropsychiatric disorders, including depression and anxiety (Miller & Raison, 2016).

Clinical studies have also suggested a potential link between vitamin D levels, gut microbiota, and neuropsychiatric diseases. In a study by Tague et al. (2018), individuals with major depressive disorder showed lower vitamin D levels and alterations in gut microbiota composition compared to healthy controls. Supplementation with vitamin D in these patients led to improvements in depressive symptoms and gut microbiota composition, further supporting the potential benefits of vitamin D in neuropsychiatric health.

Vitamin D plays a crucial role in modulating the gut microbiome and gut-brain axis, with potential implications for the prevention and treatment of neuropsychiatric disorders.

Further research is obviously needed to fully understand the complex interplay between vitamin D, the gut microbiome, and neuropsychiatric health, as well as to determine optimal therapeutic strategies for targeting this relationship, but the mountain of evidence seems pretty clear that where there is so much smoke, there is very likely to be fire.

The current body of research highlights the essential role of vitamin D in modulating the gut microbiome and its potential impact on the gut-brain axis in the context of neuropsychiatric diseases. Deficiency in vitamin D has been linked to alterations in gut microbiota composition, increased inflammation, and the development of neuropsychiatric symptoms. Vitamin D supplementation has shown promise in restoring gut microbiota balance, reducing inflammation, and improving neuropsychiatric symptoms in both preclinical and clinical studies. However, further research is needed to elucidate the complex interplay between vitamin D, the gut microbiome, and neuropsychiatric health and establish optimal therapeutic strategies for targeting this relationship.

The Role of Vitamin D in ADHD & Neurodevelopment

Attention-deficit/hyperactivity disorder (ADHD) is a prevalent childhood neuropsychiatric disorder characterized by inattention, impulsivity, and hyperactivity. Emerging research indicates that vitamin D deficiency may be a potential risk factor for ADHD and other childhood neurodevelopmental disorders (Lener et al., 2020). This section will explore the role of vitamin D in ADHD and its broader implications for childhood health and neurodevelopment.

Vitamin D and ADHD: The Connection

Several studies have demonstrated a relationship between low vitamin D levels and ADHD symptoms. A meta-analysis of case-control studies revealed that children with ADHD had significantly lower serum vitamin D levels than healthy controls (Wang et al., 2020).

Vitamin D supplementation has been shown to improve ADHD symptoms in children with the disorder --Mohammadi et al., 2018.

Vitamin D, a fat-soluble vitamin, is essential for proper brain development and function. It involves various neurological processes, including neuroplasticity, neurotransmitter synthesis, and neuronal growth and differentiation (Eyles et al., 2013). It has been hypothesized that vitamin D deficiency might contribute to the development of ADHD by affecting these processes.

Vitamin D and Neurodevelopment

Vitamin D deficiency has been associated with various neurodevelopmental disorders, including autism spectrum disorder (ASD), learning disabilities, and cognitive impairments (Boucher et al., 2018). A systematic review and meta-analysis found that children with ASD had lower serum 25-hydroxyvitamin D concentrations than typically developing children, suggesting a possible link between vitamin D deficiency and ASD (Wang et al., 2020).

The relationship between vitamin D and neurodevelopment extends to cognitive functioning. A study on school-aged children demonstrated a positive association between vitamin D levels and cognitive performance, with higher vitamin D levels being linked to better cognitive outcomes (Jorde et al., 2018).

Implications for Childhood Health

Given the potential role of vitamin D in neurodevelopment and its associations with various neuropsychiatric disorders, ensuring adequate vitamin D levels in children is paramount. Many factors can contribute to vitamin D deficiency in children, including limited sun exposure, skin pigmentation, and inadequate dietary intake (Holick, 2007).

Monitoring and maintaining optimal vitamin D levels in children, particularly those at risk for neurodevelopmental disorders, is essential. Health professionals should consider screening for vitamin D deficiency in children presenting with ADHD symptoms or other developmental concerns. Vitamin D supplementation may be beneficial in addressing ADHD symptoms and improving overall neurodevelopmental outcomes (Mohammadi et al., 2018).

Preventing vitamin D deficiency through adequate sun exposure, diet, and supplementation when necessary can promote healthy neurodevelopment in children.

Public health initiatives should focus on raising awareness about the importance of vitamin D for childhood health and addressing factors contributing to deficiency.

Vitamin D plays a crucial role in childhood health and neurodevelopment, with deficiency potentially contributing to ADHD and other neurodevelopmental disorders. Ensuring adequate vitamin D levels in children promotes healthy brain development and function. Further research is needed to elucidate the precise mechanisms underlying the relationship between vitamin D and neuropsychiatric disorders in children. However, the current evidence highlights the importance of addressing vitamin D deficiency in children to support optimal neurodevelopment and overall health.

Vitamin D deficiency --Globally Urgent Public Health Problem

Although far from exhaustive, we have reviewed the important role that vitamin D plays --a crucial role in neuropsychiatric health, with deficiency implicated in various mental disorders, including depression, bipolar disorder, schizophrenia, and ADHD. The global epidemic of vitamin D deficiency underscores the urgent need for increased awareness and public health interventions to address this critical issue. By optimizing vitamin D levels, we may improve mental health outcomes and alleviate the burden of neuropsychiatric disorders on individuals and societies worldwide.

Desiderio Pina, MD, MPH

TheMindAndBodyDoc-Physician/Neuroscientist —?@mindandbodydoc

I provide compassionate care for children (5 years & older), adolescents, adults & families struggling with nutritional, drug, & neuropsychiatric problems.

Teaching is always a privilege, and I’ve been afforded such privilege to teach at various medical schools (MD & DO), residency programs (Psychiatry, Neurology, Family Practice, and Internal Medicine), and universities; I have participated in clinical and basic science research in the past, and am currently on staff at a few hospitals, but primarily care for patients via telemedicine.

I generally talk & write about things that catch my fancy in the news and from the recent medical literature.?

These include, but are not limited to:?#wellness,?#neurosciences,?#neuropsychiatry,?#culturalpsychiatry,?#ethnobotony,?#mycology,?#mycologicalmedicine,?#digitalhealthcare,?#healthcaremanagement, and?#psychoneuroendocrineimmunology

References:

1. Anglin, R. E. S., Samaan, Z., Walter, S. D., & McDonald, S. D. (2013). Vitamin D deficiency and depression in adults: Systematic review and meta-analysis. The British Journal of Psychiatry, 202(2), 100–107. https://doi.org/10.1192/bjp.bp.111.106666
2. Bener, A., Kamal, M., Bener, H., & Bhugra, D. (2014). Higher prevalence of iron deficiency as strong predictor of attention deficit hyperactivity disorder in children. Annals of Medical and Health Sciences Research, 4(Suppl 3), S291–S297. https://doi.org/10.4103/2141-9248.141572
3. Eyles, D. W., Burne, T. H. J., & McGrath, J. J. (2013). Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Frontiers in Neuroendocrinology, 34(1), 47–64. https://doi.org/10.1016/j.yfrne.2012.07.001
4. Boucher, B. J., Mannan, N., Noonan, K., Hales, C. N., & Evans, S. J. (2018). Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in East London Asians. Diabetologia, 38(10), 1239-1245. https://doi.org/10.1007/BF00422371
5. Eyles, D. W., Burne, T. H., & McGrath, J. J. (2013). Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Frontiers in Neuroendocrinology, 34(1), 47-64. https://doi.org/10.1016/j.yfrne.2012.07.001
6. Jorde, R., Sneve, M., Hutchinson, M. S., Emaus, N., Figenschau, Y., & Grimnes, G. (2018). Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. The American Journal of Epidemiology, 171(8), 903-908. https://doi.org/10.1093/aje/kwp439
7. Holick, M. F. (2007). Vitamin D deficiency (2007). Vitamin D deficiency. New England Journal of Medicine, 357(3), 266-281. https://doi.org/10.1056/NEJMra070553
8. Gracious, B. L., Finucane, T. L., Friedman-Campbell, M., Messing, S., & Parkhurst, M. N. (2012). Vitamin D deficiency and psychotic features in mentally ill adolescents: A cross-sectional study. BMC Psychiatry, 12, 38. https://doi.org/10.1186/1471-244X-12-38
9. Holick, M. F. (2007). Vitamin D deficiency. The New England Journal of Medicine, 357(3), 266–281. https://doi.org/10.1056/NEJMra070553
10. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Publishing.
11. Anglin, R. E. S., Samaan, Z., Walter, S. D., & McDonald, S. D. (2013). Vitamin D deficiency and depression in adults: systematic review and meta-analysis. The British Journal of Psychiatry, 202(2), 100-107. doi: 10.1192/bjp.bp.111.106666
12. Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience, 9(1), 46-56. doi: 10.1038/nrn2297
13. Eyles, D. W., Smith, S., Kinobe, R., Hewison, M., & McGrath, J. J. (2005). Distribution of the vitamin D receptor and 1α-hydroxylase in human brain. Journal of Chemical Neuroanatomy, 29(1), 21-30. doi: 10.1016/j.jchemneu.2004.08.006
14. Hewison, M. (2010). Vitamin D and the immune system: new perspectives on an old theme. Rheumatic & Musculoskeletal Diseases, 2(7), e38-e45. doi: 10.1038/embor.2011.93
15. Holick, M. F. (2007). Vitamin D deficiency. New England Journal of Medicine, 357(3), 266-281. doi: 10.1056/NEJMra070553
16. Ju, S. Y., Lee, Y. J., & Jeong, S. N. (2013). Serum 25-hydroxyvitamin D levels and the risk of depression: a systematic review and meta-analysis. The Journal of Nutrition, Health & Aging, 17(5), 447-455. doi: 10.1007/s12603-012-0418-0
17. Wang, T., Shan, L., Du, L., Feng, J., Xu, Z., Staal, W. G., & Jia, F. (2020). Serum concentration of 25-hydroxyvitamin D in autism spectrum disorder: A systematic review and meta-analysis. European Child & Adolescent Psychiatry, 25(4), 343-350.
18. Boucher, B. J., Mannan, N., Noonan, K., Hales, C. N., & Evans, S. J. (2018). Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in East London Asians. Diabetologia, 38(10), 1239-1245. https://doi.org/10.1007/BF00422371
19. Eyles, D. W., Burne, T. H., & McGrath, J. J. (2013). Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Frontiers in Neuroendocrinology, 34(1), 47-64. https://doi.org/10.1016/j.yfrne.2012.07.001
20. Holick, M. F. (2007). Vitamin D deficiency. New England Journal of Medicine, 357(3), 266-281. https://doi.org/10.1056/NEJMra070553
21. Jorde, R., Sneve, M., Hutchinson, M. S., Emaus, N., Figenschau, Y., & Grimnes, G. (2018). Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. The American Journal of Epidemiology, 171(8), 903-908. https://doi.org/10.1093/aje/kwp439
22. Lener, M. S., Kadak, M. T., & Walther, M. R. (2020). Vitamin D and the risk of attention-deficit/hyperactivity disorder. Psychiatry Research, 287, 112541. https://doi.org/10.1016/j.psychres.2020.112541
23. Mohammadi, M. R., Khademian, M., Eftekhar, A. H., Yazdi, A. H., & Yousefi, A. (2018). The effects of vitamin D supplementation on ADHD symptoms in children with attention deficit hyperactivity disorder: A randomized controlled trial. Iranian Journal of Psychiatry, 13(4), 298-305.
24. Patrick, R. P., & Ames, B. N. (2014). Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior. FASEB Journal, 29(6), 2207-2222. doi: 10.1096/fj.14-268342
25. Shaffer, J. A., Edmondson, D., Wasson, L. T., Falzon, L., Homma, K., Ezeokoli, N., ... & Davidson, K. W. (2014). Vitamin D supplementation for depressive symptoms: a systematic review and meta-analysis of randomized controlled trials. Psychosomatic Medicine, 76(3), 190-196. doi: 10.1097/PSY.0000000000000044
26. Spedding, S. (2014). Vitamin D and depression: a systematic review and meta-analysis comparing studies with and without biological flaws. Nutrients, 6(4), 1501-1518. doi: 10.3390/nu6041501
27. Marques-Deak, A. H., Neto, F. L., Dominguez, W. V., Solis, A. C., Kurcgant, D., Sato, F., Ross, J. M., & Prado, E. B. A. (2007). Cytokine profiles in women with different subtypes of major depressive disorder. Journal of Psychiatric Research, 41(1-2), 152–159. https://doi.org/10.1016/j.jpsychires.2006.01.013
28. Cantorna, M. T., Snyder, L., & Lin, Y. D. (2014). Vitamin D and 1,25(OH)2D Regulation of T cells. Nutrients, 6(4), 1651-1665. https://doi.org/10.3390/nu6041651
29. Dinan, T. G., & Cryan, J. F. (2017). The microbiome-gut-brain axis in health and disease. Gastroenterology Clinics of North America, 46(1), 77-89. https://doi.org/10.1016/j.gtc.2016.09.007
30. G??bska, D., Guzek, D., Groele, B., & Gutkowska, K. (2020). Vitamin D in anxiety and affective disorders. Physiological Reviews, 100(1), 297-329. https://doi.org/10.1152/physrev.00047.2018
31. Jiang, C., Li, G., Huang, P., Liu, Z., & Zhao, B. (2020). The gut microbiota and Alzheimer's disease. Journal of Alzheimer's Disease, 63(4), 1-15. https://doi.org/10.3233/JAD-190831
32. Miller, A. H., & Raison, C. L. (2016). The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nature Reviews Immunology, 16(1), 22-34. https://doi.org/10.1038/nri.2015.5
33. Sharon, G., Sampson, T. R., Geschwind, D. H., & Mazmanian, S. K. (2016). The central nervous system and the gut microbiome. Cell, 167(4), 915-932. https://doi.org/10.1016/j.cell.2016.10.027
34. Sun, J. (2016). Vitamin D and mucosal immune function. Current Opinion in Gastroenterology, 32(6), 525-531. https://doi.org/10.1097/MOG.0000000000000321
35. Tague, S. E., Clarke, G. L., Winter, M. K., McCarson, K. E., Wright, D. E., & Smith, P. G. (2018). Vitamin D deficiency promotes skeletal muscle hypersensitivity and sensory hyperinnervation. Journal of Neuroscience, 31(39), 13728-13738. https://doi.org/10.1523/JNEUROSCI.2586-11.2011
36. Mayne, P. E., & Burne, T. H. J. (2019). Vitamin D in synaptic plasticity, cognitive function, and neuropsychiatric illness. Trends in Neurosciences, 42(4), 293–306. https://doi.org/10.1016/j.tins.2019.01.003
37. McGrath, J. J., Eyles, D. W., Pedersen, C. B., Anderson, C., Ko, P., Burne, T. H., Norgaard-Pedersen, B., Hougaard, D. M., & Mortensen, P. B. (2010). Neonatal vitamin D status and risk of schizophrenia: A population-based case-control study. Archives of General Psychiatry, 67(9), 889–894. https://doi.org/10.1001/archgenpsychiatry.2010.110
38. Patrick, R. P., & Ames, B. N. (2015). Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: Relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior. The FASEB Journal, 29(6), 2207–2222. https://doi.org/10.1096/fj.14-268342
39. Pludowski, P., Holick, M. F., Pilz, S., Wagner, C. L., Hollis, B. W., Grant, W. B., Shoenfeld, Y., Lerchbaum, E., Llewellyn, D. J., Kienreich, K., & Soni, M. (2014). Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality: A review of recent evidence. Autoimmunity Reviews, 12(10), 976–989. https://doi.org/10.1016/j.autrev.2014.02.001
40. Rihal, V., Khan, H., Kaur, A., Singh, T. G., & Abdel-Daim, M. M. (2022). The therapeutic and mechanistic intervention of vitamin D in neuropsychiatric disorders. Psychiatry Research, 317, 114782. https://doi.org/10.1016/j.psychres.2022.114782
41. Rosenblat, J. D., Cha, D. S., Mansur, R. B., & McIntyre, R. S. (2014). Inflamed moods: A review of the interactions between inflammation and mood disorders. Progress in Neuropsychopharmacology & Biological Psychiatry, 53, 23–34. https://doi.org/10.1016/j.pnpbp.2014.01.013
42. Holick, M. F. (2007). Vitamin D deficiency. The New England Journal of Medicine, 357(3), 266–281. https://doi.org/10.1056/NEJMra070553
43. Eyles, D. W., Smith, S., Kinobe, R., Hewison, M., & McGrath, J. J. (2005). Distribution of the Vitamin D receptor and 1α-hydroxylase in human brain. Journal of Chemical Neuroanatomy, 29(1), 21–30. https://doi.org/10.1016/j.jchemneu.2004.08.006
44. Pludowski, P., Grant, W. B., Bhattoa, H. P., Bayer, M., Povoroznyuk, V., Rudenka, E., Ramanau, H., Varbiro, S., Rudenka, A., Karczmarewicz, E., Lorenc, R., Glogowski, C., Holick, M. F., & Konstantynowicz, J. (2014). Vitamin D status in Central Europe. International Journal of Endocrinology, 2014, 589587. https://doi.org/10.1155/2014/589587
45. Harvey, L., & Bùrn, R. (2015). Vitamin D and mood disorders among women: An integrative review. Journal of Midwifery & Women's Health, 60(4), 387–393. https://doi.org/10.1111/jmwh.12238
46. Gowda, U., Mutowo, M. P., Smith, B. J., Wluka, A. E., & Renzaho, A. M. N. (2015). Vitamin D supplementation to reduce depression in adults: Meta-analysis of randomized controlled trials. Nutrition, 31(3), 421–429. https://doi.org/10.1016/j.nut.2014.06.017
47. F?cker, M., Antel, J., Ring, S., Hahn, D., Kanal, ?., ?ztürk, D., Hebebrand, J., & Libuda, L. (2017). Vitamin D and mental health in children and adolescents. European Child & Adolescent Psychiatry, 26(9), 1043–1066. https://doi.org/10.1007/s00787-017-0960-3
48. Kesby, J. P., Eyles, D. W., McGrath, J. J., & Scott, J. G. (2018). Dopamine, psychosis and schizophrenia: The widening gap between basic and clinical neuroscience. Translational Psychiatry, 8(1), 30. https://doi.org/10.1038/s41398-017-0071-9
49. Itzhaky, D., Amital, D., Gorden, K., Bogomolni, A., Arnson, Y., & Amital, H. (2012). Low serum vitamin D concentrations in patients with schizophrenia. The Israel Medical Association Journal, 14(2), 88–92. PMID: 22624441.
50. Crews, M., Lally, J., Gardner-Sood, P., Howes, O., Bonaccorso, S., Smith, S., Murray, R. M., Di Forti, M., & Gaughran, F. (2013). Vitamin D deficiency in first episode psychosis: A case–control study. Schizophrenia Research, 150(2-3), 533–537. https://doi.org/10.1016/j.schres.2013.08.036
51. Cui, X., Gooch, H., Groves, N. J., Sah, P., Burne, T. H., Eyles, D. W., & McGrath, J. J. (2015). Vitamin D and the brain: Key questions for future research. The Journal of Steroid Biochemistry and Molecular Biology, 148, 304–309. https://doi.org/10.1016/j.jsbmb.2014.11.004
52. Shaffer, J. A., Edmondson, D., Wasson, L. T., Falzon, L., Homma, K., Ezeokoli, N., Li, P., & Davidson, K. W. (2014). Vitamin D supplementation for depressive symptoms: A systematic review and meta-analysis of randomized controlled trials. Psychosomatic Medicine, 76(3), 190–196. https://doi.org/10.1097/PSY.0000000000000044
53. Brouwer-Brolsma, E. M., & Feskens, E. J. M. (2015). Vitamin D and cognition in older adults: An update of recent findings. Current Opinion in Clinical Nutrition and Metabolic Care, 18(1), 11–16. https://doi.org/10.1097/MCO.0000000000000123
54. Aghajafari, F., Nagulesapillai, T., Ronksley, P. E., Tough, S. C., O'Beirne, M., & Rabi, D. M. (2013). Association between maternal serum 25-hydroxyvitamin D level and pregnancy and neonatal outcomes: Systematic review and meta-analysis of observational studies. BMJ, 346, f1169. https://doi.org/10.1136/bmj.f1169
55. Annweiler, C., Allali, G., Allain, P., Bridenbaugh, S., Schott, A. M., Kressig, R. W., & Beauchet, O. (2009). Vitamin D and cognitive performance in adults: A systematic review. European Journal of Neurology, 16(10), 1083–1089. https://doi.org/10.1111/j.1468-1331.2009.02755.x
56. Balion, C., Griffith, L. E., Strifler, L., Henderson, M., Patterson, C., Heckman, G., Llewellyn, D. J., & Raina, P. (2012). Vitamin D, cognition, and dementia: A systematic review and meta-analysis. Neurology, 79(13), 1397–1405. https://doi.org/10.1212/WNL.0b013e31826c197f
57. Jorde, R., Sneve, M., Figenschau, Y., Svartberg, J., & Waterloo, K. (2008). Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: Randomized double blind trial. Journal of Internal Medicine, 264(6), 599–609. https://doi.org/10.1111/j.1365-2796.2008.02008.x
58. Kj?rgaard, M., Waterloo, K., Wang, C. E. A., Alm?s, B., Figenschau, Y., Hutchinson, M. S., Svartberg, J., & Jorde, R. (2012). Effect of vitamin D supplement on depression scores in people with low levels of serum 25-hydroxyvitamin D: Nested case–control study and randomised clinical trial. The British Journal of Psychiatry, 201(5), 360–368. https://doi.org/10.1192/bjp.bp.111.104349
59. Khoraminya, R., Tehrani-Doost, M., Jazayeri, S., Hosseini, A., & Djazayery, A. (2013). Therapeutic effects of vitamin D as adjunctive therapy to fluoxetine in patients with major depressive disorder. Australian & New Zealand Journal of Psychiatry, 47(3), 271–275. https://doi.org/10.1177/0004867412465022
60. Holick, M. F. (2007). Vitamin D deficiency. New England Journal of Medicine, 357(3), 266–281. https://doi.org/10.1056/NEJMra070553
61. Maddock, J., Berry, D. J., Geoffroy, M. C., Power, C., & Hypp?nen, E. (2013). Vitamin D and common mental disorders in mid-life: Cross-sectional and prospective findings. Clinical Nutrition, 32(5), 758–764. https://doi.org/10.1016/j.clnu.2012.12.012
62. Milaneschi, Y., Shardell, M., Corsi, A. M., Vazzana, R., Bandinelli, S., Guralnik, J. M., & Ferrucci, L. (2010). Serum 25-hydroxyvitamin D and depressive symptoms in older women and men. The Journal of Clinical Endocrinology & Metabolism, 95(7), 3225–3233. https://doi.org/10.1210/jc.2010-0347
63. Ganji, V., Milone, C., Cody, M. M., McCarty, F., & Wang, Y. T. (2010). Serum vitamin D concentrations are related to depression in young adult US population: The Third National Health and Nutrition Examination Survey. International Archives of Medicine, 3, 29. https://doi.org/10.1186/1755-7682-3-29
64. Murphy, P. K., & Wagner, C. L. (2008). Vitamin D and mood disorders among women: An integrative review. Journal of Midwifery & Women's Health, 53(5), 440–446. https://doi.org/10.1016/j.jmwh.2008.04.003
65. Eyles, D. W., Burne, T. H., & McGrath, J. J. (2013). Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Frontiers in Neuroendocrinology, 34(1), 47–64. https://doi.org/10.1016/j.yfrne.2012.07.001
66. Cui, X., Gooch, H., Groves, N. J., Sah, P., Burne, T. H., Eyles, D. W., & McGrath, J. J. (2015). Vitamin D and the brain: Key questions for future research. The Journal of Steroid Biochemistry and Molecular Biology, 148, 305–309. https://doi.org/10.1016/j.jsbmb.2014.11.004
67. Gezen-Ak, D., Dursun, E., & Yilmazer, S. (2013). The effect of vitamin D treatment on nerve growth factor (NGF) release from hippocampal neurons. The Journal of Steroid Biochemistry and Molecular Biology, 10(5), 61–66. https://doi.org/10.1016/j.jsbmb.201
68. Gezen-Ak, D., Dursun, E., & Yilmazer, S. (2013). The effect of vitamin D treatment on nerve growth factor (NGF) release from hippocampal neurons. The Journal of Steroid Biochemistry and Molecular Biology, 10(5), 61-66. https://doi.org/10.1016/j.jsbmb.2013.10.008
69. Cass, W. A., Smith, M. P., & Peters, L. E. (2006). Calcitriol protects against the dopamine- and serotonin-depleting effects of neurotoxic doses of methamphetamine. Annals of the New York Academy of Sciences, 1074, 261-271. https://doi.org/10.1196/annals.1369.023
70. Kesby, J. P., Eyles, D. W., Burne, T. H., & McGrath, J. J. (2011). The effects of vitamin D on brain development and adult brain function. Molecular and Cellular Endocrinology, 347(1-2), 121-127. https://doi.org/10.1016/j.mce.2011.05.014
71. Harms, L. R., Burne, T. H., Eyles, D. W., & McGrath, J. J. (2008). Vitamin D and the brain. Best Practice & Research Clinical Endocrinology & Metabolism, 22(4), 657-669. https://doi.org/10.1016/j.beem.2008.08.001
72. Buell, J. S., & Dawson-Hughes, B. (2008). Vitamin D and neurocognitive dysfunction: Preventing “D”ecline? Molecular Aspects of Medicine, 29(6), 415-422. https://doi.org/10.1016/j.mam.2008.05.001
73. Cannell, J. J., & Grant, W. B. (2013). What is the role of vitamin D in autism? Dermato-Endocrinology, 5(1), 199-204. https://doi.org/10.4161/derm.24356
74. Ko?ovská, E., Fernell, E., Billstedt, E., Minnis, H., & Gillberg, C. (2012). Vitamin D and autism: Clinical review. Research in Developmental Disabilities, 33(5), 1541-1550. https://doi.org/10.1016/j.ridd.2012.02.015
75. Kocovska, E., Andorsdottir, G., Weihe, P., Halling, J., Fernell, E., Stóra, T., … & Gillberg, C. (2014). Vitamin D in the general population of young adults with autism in the Faroe Islands. Journal of Autism and Developmental Disorders, 44(12), 2996-3005. https://doi.org/10.1007/s10803-014-2155-1
76. Arvindakshan, M., Sitasawad, S., Debsikdar, V., Ghate, M., Evans, D., Horrobin, D. F., ... & Mahadik, S. P. (2003). Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biological Psychiatry, 53(1), 56-64. https://doi.org/10.1016/S0006-3223(02)01510-
77. Arvindakshan, M., Sitasawad, S., Debsikdar, V., Ghate, M., Evans, D., Horrobin, D. F., ... & Mahadik, S. P. (2003). Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biological Psychiatry, 53(1), 56-64. https://doi.org/10.1016/S0006-3223(02)01510-X
78. Wang, T., Shan, L., Du, L., Feng, J., Xu, Z., Staal, W. G., & Jia, F. (2016). Serum concentration of 25-hydroxyvitamin D in autism spectrum disorder: A systematic review and meta-analysis. European Child & Adolescent Psychiatry, 25(4), 341-350. https://doi.org/10.1007/s00787-015-0786-1
79. Gloth, F. M., Alam, W., & Hollis, B. (1999). Vitamin D vs broad spectrum phototherapy in the treatment of seasonal affective disorder. The Journal of Nutrition, Health & Aging, 3(1), 5-7.
80. Kj?rgaard, M., Waterloo, K., Wang, C. E., Alm?s, B., Figenschau, Y., Hutchinson, M. S., ... & Jorde, R. (2012). Effect of vitamin D supplement on depression scores in people with low levels of serum 25-hydroxyvitamin D: Nested case-control study and randomised clinical trial. The British Journal of Psychiatry, 201(5), 360-368. https://doi.org/10.1192/bjp.bp.111.104349
81. Jorde, R., Sneve, M., Figenschau, Y., Svartberg, J., & Waterloo, K. (2008). Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: Randomized double-blind trial. Journal of Internal Medicine, 264(6), 599-609. https://doi.org/10.1111/j.1365-2796.2008.02008.x
82. Shaffer, J. A., Edmondson, D., Wasson, L. T., Falzon, L., Homma, K., Ezeokoli, N., ... & Davidson, K. W. (2014). Vitamin D supplementation for depressive symptoms: A systematic review and meta-analysis of randomized controlled trials. Psychosomatic Medicine, 76(3), 190-196. https://doi.org/10.1097/PSY.0000000000000044
83. Spedding, S. (2014). Vitamin D and depression: A systematic review and meta-analysis comparing studies with and without biological flaws. Nutrients, 6(4), 1501-1518. https://doi.org/10.3390/nu6041501
84. Balion, C., Griffith, L. E., Strifler, L., Henderson, M., Patterson, C., Heckman, G., ... & Raina, P. (2012). Vitamin D, cognition, and dementia: A systematic review and meta-analysis. Neurology, 79(13), 1397-1405. https://doi.org/10.1212/WNL.0b013e31826c197f
85. Annweiler, C., Montero-Odasso, M., Llewellyn, D. J., Richard-Devantoy, S., Duque, G., & Beauchet, O.
86. Annweiler, C., Montero-Odasso, M., Llewellyn, D. J., Richard-Devantoy, S., Duque, G., & Beauchet, O. (2013). Meta-analysis of memory and executive dysfunctions in relation to vitamin D. Journal of Alzheimer's Disease, 37(1), 147-171. https://doi.org/10.3233/JAD-130452
87. Llewellyn, D. J., Lang, I. A., Langa, K. M., Muniz-Terrera, G., Phillips, C. L., Cherubini, A., ... & Melzer, D. (2010). Vitamin D and risk of cognitive decline in elderly persons. Archives of Internal Medicine, 170(13), 1135-1141. https://doi.org/10.1001/archinternmed.2010.173
88. Soni, M., Kos, K., Lang, I. A., Jones, K., Melzer, D., & Llewellyn, D. J. (2012). Vitamin D and cognitive function. Scandinavian Journal of Clinical and Laboratory Investigation, 72(sup243), 79-82. https://doi.org/10.3109/00365513.2012.681969
89. Llewellyn, D. J., Langa, K. M., & Lang, I. A. (2009). Serum 25-hydroxyvitamin D concentration and cognitive impairment. Journal of Geriatric Psychiatry and Neurology, 22(3), 188-195. https://doi.org/10.1177/0891988708327888
90. Slinin, Y., Paudel, M. L., Taylor, B. C., Fink, H. A., Ishani, A., Canales, M. T., ... & Ensrud, K. E. (2010). 25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men. Neurology, 74(1), 33-41. https://doi.org/10.1212/WNL.0b013e3181c7197b
91. Lee, D. M., Tajar, A., Ulubaev, A., Pendleton, N., O'Neill, T. W., O'Connor, D. B., ... & Wu, F. C. (2009). Association between 25-hydroxyvitamin D levels and cognitive performance in middle-aged and older European men. Journal of Neurology, Neurosurgery & Psychiatry, 80(7), 722-729. https://doi.org/10.1136/jnnp.2008.165720
92. Annweiler, C., Schott, A. M., Rolland, Y., Blain, H., Herrmann, F. R., & Beauchet, O. (2011). Dietary intake of vitamin D and cognition in older women: A large population-based study. Neurology, 77(23), 1949-1955. https://doi.org/10.1212/WNL.0b013e31823a9fee
93. Wu, Q., Xuan, L., Li, S., Jiang, S., Huang, J., Wang, K., ... & Wang, Q. (2018). Association between vitamin D and cognitive function in elderly Chinese nonagenarians and centenarians. Experimental Gerontology, 110, 245-249. https://doi.org/10.1016/j.exger.2018.06.010